#MGC Pharmaceuticals
#MGC Pharmaceuticals · page 2
- Press releases
MGC Pharmaceuticals Enters Partnership With Sciensus Rare For The Distribution Of CannEpil And CogniCann In The EU And UK
· MGC EXECUTES supply and distribution agreement with international pharmaceuticals company Sciensus Rare. · Sciensus Rare is an established international pharmaceutical services company, specialising in the provision of rare disease medicines through a network of decentralised clinical trials, early access programs and licensed distribution programs. · Sciensus Rare appointed the exclusive distributor of MGC Pharma’s CannEpil® and CogniCann®…
- Pharmaceutical
One Year After The First Cannabis Stocks Joined The LSE, Could We See A Fresh Run Of Cannabis IPOs This Year?
FEBRUARY 2022 marked the one-year anniversary of MGC Pharmaceuticals IPO on the London Stock Exchange, which saw cannabis stocks traded on the platform for the first time in its 320-year history.
- Markets & Stocks
EU Cannabis Stocks Review: How Ukraine Crisis Is Impacting Cannabis Stocks, Chill Brands’ Revenue Could Be $1m Less & More From Tilray and MGC Pharma
LAST week began with a number of European cannabis stocks levelling out following dramatic declines days earlier in reaction to Russia’s invasion of Ukraine.
- News
MGC Pharmaceuticals Says It May Need A Further Capital Raise As Losses Grow
MGC Pharmaceuticals (MXC) has reported its ‘its strongest half-year result to date’ seeing sales more than triple year-on-year, helping lift its stock price out of an all-time low.
- Pharmaceutical
EU Cannabis Stocks Review: Love Hemp jumps 60%, OCT sees recovery & more from Cellular Goods, Chill Brands and MGC Pharma
On the 1-year anniversary of the first cannabis company to list on the London Stock Exchange, we examine the reaction to a number of significant announcements from some of the UK’s biggest cannabis players, making for an eventful week in the markets.
- Medical
MGC Pharma Reports Strongest Ever Sales as Key Drug Approvals Remain in Limbo
MGC Pharmaceutical has reported its strongest ever quarterly sales figures, but a lack of significant progress on its drug trials and regulatory approvals saw a muted response from investors.
- Pharmaceutical
London Stock Exchange Cannabis Company Values Down Almost £200m From Early Peaks
THIS has been a transformative year for the European cannabis industry, with growing liberalisation across the continent opening the floodgates for patients and investors alike.
- Markets & Stocks
MGC Pharmaceuticals Tells Shareholders Pending Deal Could ‘Transform Finances Overnight’
MGC Pharmaceuticals told shareholders attending its Annual General Meeting (AGM) that it is on track to deliver ‘far and away the best financial performance of the company’ in the coming months.
- Pharmaceutical
Plans Unveiled For First National Health Service-Backed Medical Cannabis Clinical Trial
AFTER launching a patient registry earlier this year further signs the UK’s National Health Service is warming to cannabis medicine have emerged with news of the potential launch of a clinical trial.
- Pharmaceutical
New Listing Proposals Could Exclude Cannabis Startups From The London Stock Exchange
PROPOSALS to set a minimum valuation level for companies looking to list on the London Stock Exchange could limit the number of cannabis entrants to the market.
- News
MGC Pharma Secures €450,000 European Funding To Boost Research In Its CannaHub
MGC Pharmaceuticals is preparing to move forward with novel, unique and disruptive research in the medical cannabis sector after securing around €450,000 in flagship European Union (EU) funding.
- Markets & Stocks
LSE Cannabis Debutant Company MGC Pharma Set ‘To Break Even This Year’
THE London Stock Exchange’s medical cannabis debutant MGC Pharmaceuticals has released is first quarterly update since listing showing record revenues of almost £500,000.
